Blume Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41.9K | Hold |
800
| – | – | 0.01% | 214 |
|
|
2026
Q1 | $44.2K | Buy |
+800
| New | +$43.4K | 0.01% | 206 |
|
|
2025
Q2 | – | Sell |
-360
| Closed | -$13.9K | – | 490 |
|
|
2025
Q1 | $13.9K | Hold |
360
| – | – | ﹤0.01% | 253 |
|
|
2024
Q4 | $12.2K | Hold |
360
| – | – | ﹤0.01% | 249 |
|
|
2024
Q3 | $14.7K | Sell |
360
-2,720
| -88% | -$111K | ﹤0.01% | 253 |
|
|
2024
Q2 | $119K | Hold |
3,080
| – | – | 0.03% | 135 |
|
|
2024
Q1 | $132K | Hold |
3,080
| – | – | 0.03% | 129 |
|
|
2023
Q4 | $114K | Sell |
3,080
-40
| -1% | -$1.44K | 0.03% | 129 |
|
|
2023
Q3 | $113K | Sell |
3,120
-300
| -9% | -$10.6K | 0.03% | 128 |
|
|
2023
Q2 | $122K | Hold |
3,420
| – | – | 0.04% | 118 |
|
|
2023
Q1 | $122K | Buy |
3,420
+1,000
| +41% | +$35K | 0.04% | 116 |
|
|
2022
Q4 | $85K | Buy |
2,420
+960
| +66% | +$32K | 0.03% | 135 |
|
|
2022
Q3 | $43K | Buy |
1,460
+500
| +52% | +$18.9K | 0.02% | 162 |
|
|
2022
Q2 | $52K | Sell |
960
-1,400
| -59% | -$77.3K | 0.02% | 157 |
|
|
2022
Q1 | $129K | Buy |
2,360
+160
| +7% | +$8.69K | 0.04% | 111 |
|
|
2021
Q4 | $121K | Buy |
2,200
+595
| +37% | +$31K | 0.04% | 127 |
|
|
2021
Q3 | $77K | Buy |
+1,605
| New | +$80.6K | 0.03% | 144 |
|
|
2019
Q2 | – | Sell |
-90
| Closed | -$5K | – | 223 |
|
|
2019
Q1 | $5K | Hold |
90
| – | – | ﹤0.01% | 207 |
|
|
2018
Q4 | $4K | Hold |
90
| – | – | ﹤0.01% | 205 |
|
|
2018
Q3 | $5K | Sell |
90
-38,384
| -100% | -$1.95M | ﹤0.01% | 179 |
|
|
2018
Q2 | $1.94M | Sell |
38,474
-420
| -1% | -$21.2K | 1.06% | 31 |
|
|
2018
Q1 | $1.9M | Buy |
38,894
+38,668
| +17,110% | +$1.8M | 1.06% | 29 |
|
|
2017
Q4 | $10K | Hold |
226
| – | – | 0.01% | 188 |
|
|
2017
Q3 | $11K | Hold |
226
| – | – | 0.01% | 191 |
|
|
2017
Q2 | $12K | Hold |
226
| – | – | 0.01% | 155 |
|
|
2017
Q1 | $12K | Hold |
226
| – | – | 0.01% | 151 |
|
|
2016
Q4 | $11K | Hold |
226
| – | – | 0.01% | 159 |
|
|
2016
Q3 | $12K | Hold |
226
| – | – | 0.01% | 145 |
|
|
2016
Q2 | $12K | Hold |
226
| – | – | 0.01% | 163 |
|
|
2016
Q1 | $11K | Hold |
226
| – | – | 0.01% | 173 |
|
|
2015
Q4 | $11K | Sell |
226
-96
| -30% | -$4.89K | 0.01% | 179 |
|
|
2015
Q3 | $15K | Hold |
322
| – | – | 0.01% | 159 |
|
|
2015
Q2 | $17K | Hold |
322
| – | – | 0.01% | 164 |
|
|
2015
Q1 | $19K | Sell |
322
-160
| -33% | -$9.17K | 0.01% | 182 |
|
|
2014
Q4 | $26K | Buy |
482
+250
| +108% | +$14K | 0.02% | 180 |
|
|
2014
Q3 | $13K | Hold |
232
| – | – | 0.01% | 144 |
|
|
2014
Q2 | $16K | Hold |
232
| – | – | 0.01% | 151 |
|
|
2014
Q1 | $15K | Hold |
232
| – | – | 0.01% | 170 |
|
|
2013
Q4 | $15K | Buy |
+232
| New | +$15K | 0.01% | 193 |
|
Other funds holding GSK
JEST
Blume Capital Management's GSK Position: Q2 2026 in Review
Blume Capital Management held its GSK (GSK) position steady in Q2 2026 at 800 shares worth $41.9K. The position accounts for 0.01% of the portfolio, ranked #214.
Blume Capital Management first reported a position in GSK in Q4 2013 and has held it in 39 quarters since. The position peaked at $1.94M in Q2 2018. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Blume Capital Management held 800 shares of GSK worth $41.9K as of Q2 2026.
- Blume Capital Management left its GSK share count unchanged in Q2 2026.
- GSK made up 0.01% of Blume Capital Management's portfolio in Q2 2026, its #214 holding.
- Blume Capital Management first reported a position in GSK in Q4 2013 and has held it in 39 quarters since.
- Blume Capital Management's GSK position peaked at $1.94M in Q2 2018.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Blume Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.